Concomitant use of antipsychotics and drugs that may prolong the QT interval

被引:24
作者
Roe, CM
Odell, KW
Henderson, RR
机构
[1] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA
[3] Express Scripts Inc, Bloomington, MN USA
[4] Express Scripts Inc, St Louis, MO USA
关键词
D O I
10.1097/00004714-200304000-00013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1, 139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 5 1 % of QT antipsychotic group members used other QT drugs concomitantly for at least I day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled (p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.
引用
收藏
页码:197 / 200
页数:4
相关论文
共 17 条
[1]  
[Anonymous], 2001, EXPL BIOL CONTR HUM
[2]   A CHRONIC DISEASE SCORE WITH EMPIRICALLY DERIVED WEIGHTS [J].
CLARK, DO ;
VONKORFF, M ;
SAUNDERS, K ;
BALUCH, WM ;
SIMON, GE .
MEDICAL CARE, 1995, 33 (08) :783-795
[3]   QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience [J].
De Ponti, F ;
Poluzzi, E ;
Montanaro, N .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) :1-18
[4]  
LEHMANN M, 2001, GENDER DIFFERENCES L
[5]   FEMALE GENDER AS A RISK FACTOR FOR TORSADES-DE-POINTES ASSOCIATED WITH CARDIOVASCULAR DRUGS [J].
MAKKAR, RR ;
FROMM, BS ;
STEINMAN, RT ;
MEISSNER, MD ;
LEHMANN, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (21) :2590-2597
[6]   ELECTROCARDIOGRAPHIC QUANTITATION OF VENTRICULAR REPOLARIZATION [J].
MERRI, M ;
BENHORIN, J ;
ALBERTI, M ;
LOCATI, E ;
MOSS, AJ .
CIRCULATION, 1989, 80 (05) :1301-1308
[7]   The population's use of pharmaceuticals [J].
Metge, C ;
Black, C ;
Peterson, S ;
Kozyrskyj, AL .
MEDICAL CARE, 1999, 37 (06) :JS42-JS59
[8]   Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes [J].
Owens, RC .
PHARMACOTHERAPY, 2001, 21 (03) :301-319
[9]  
RAUTAHARJU PM, 1992, CAN J CARDIOL, V8, P690
[10]   QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients [J].
Reilly, JG ;
Ayis, SA ;
Ferrier, IN ;
Jones, SJ ;
Thomas, SHL .
LANCET, 2000, 355 (9209) :1048-1052